Galectin Therapeutics clears FDA Type C milestone, shares react on NASDAQ
23.06.2026 - 19:54:09 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 19:51.
Galectin Therapeutics (US3631621074) has put regulatory clarity for its liver drug belapectin at the center of trade today. The NASDAQ-listed biotech reports a positive Type C meeting with the US Food and Drug Administration, setting out the primary endpoint and Phase 3 path in MASH cirrhosis and portal hypertension as detailed in its latest investor update. Company press release on the FDA Type C meeting
What the FDA meeting changes
According to Galectin Therapeutics, the FDA has agreed on a primary endpoint for a planned Phase 3 trial of belapectin in patients with MASH cirrhosis and portal hypertension, giving the company a clear regulatory path toward potential full approval. The company intends to file the Phase 3 protocol in the third quarter of 2026 and is actively exploring strategic and financial partnership opportunities to support continued development, as outlined in its June regulatory communication. MarketWatch coverage of the FDA meeting and Phase 3 plans
In the same announcement, Galectin Therapeutics reiterated that belapectin targets advanced MASH cirrhosis, a form of liver disease associated with metabolic dysfunction that has limited treatment options today. The company highlights that agreement on the study design and framework allows it to begin detailed Phase 3 preparations while it evaluates different development routes and potential strategic collaborations to share costs and risks, a common pattern among US mid-cap biotech names on NASDAQ. IR release summary on belapectin development plans
How shares respond on NASDAQ Tuesday
The FDA update has triggered a marked reaction in Galectin Therapeutics shares on NASDAQ. MarketWatch reports that on Tuesday afternoon the stock rose by around 21 percent to intraday levels near 3.38 US dollars, even though it remains approximately 19 percent lower year to date, illustrating how single regulatory milestones can outweigh broader performance trends in the short term for clinical-stage biotech names. MarketWatch intraday move and YTD performance
Technical platforms such as TradingKey show Galectin Therapeutics with recent closing prices just under 2.80 US dollars before the latest jump, a market capitalization around 184 million US dollars and a loss-making trailing twelve-month price-earnings ratio typical for a late-stage development biotech. Several short-term moving averages indicate buy signals, with the site listing multiple bullish indications across MA5 to MA200, suggesting that the chart picture has turned more constructive after the regulatory news, even as medium-term volatility remains high. TradingKey technical analysis on GALT
All news and analysis on the Galectin Therapeutics shares
Further reports, price data and regulatory filings on Galectin Therapeutics are bundled on the AD HOC NEWS topic page and the company's investor-relations site.
The drug program behind the stock
Galectin Therapeutics builds its investment story around belapectin, a galectin-3 inhibitor designed to modify disease progression in advanced MASH cirrhosis by modulating fibrogenesis, as highlighted in recent oral and poster presentations at the EASL 2026 liver congress in Barcelona. Data from the NAVIGATE Phase 2b trial suggest that belapectin can reduce the development of esophageal varices in high-risk patients by shifting the Pro-C3/CTX-III ratio and improving Baveno portal hypertension criteria, putting the drug in a differentiated position within the crowded metabolic liver-disease pipeline. EASL NAVIGATE trial presentation summary
Where the shares trade today
Galectin Therapeutics shares (US3631621074) trade on NASDAQ, with recent closing data showing prices around 2.79 to 2.80 US dollars and an indicated market capitalization close to 184 million US dollars as of the latest 2026-06-22 session. The quoted levels and market cap reflect pre- and post-announcement trading ranges; investors should always check the most current NASDAQ print and official exchange data before making decisions based on intraday moves or technical indicators.
Key data on the Galectin Therapeutics shares
- Company: Galectin Therapeutics Inc.
- ISIN: US3631621074
- WKN: A1JJ3K
- Ticker: GALT
- Trading venue: NASDAQ
- Price (as of 2026-06-22, 16:00): 2.79 USD
- Market cap: 184.40 million USD (as of 2026-06-22)
- Sector / industry: Biotechnology / Pharmaceuticals
- Index membership: None of the major headline indices such as S&P 500 or NASDAQ-100
- Next earnings date: not officially scheduled
Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell any security, or a solicitation of an offer to buy or sell. All data are based on publicly available sources believed to be reliable at the time of writing, but may change without notice. Investors should conduct their own research or consult a qualified financial advisor before making investment decisions.
